Comparative Pharmacology
Head-to-head clinical analysis: BYOOVIZ versus ZALTRAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYOOVIZ versus ZALTRAP.
BYOOVIZ vs ZALTRAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYOOVIZ (bevacizumab-maly) is a vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A and prevents its interaction with receptors VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Vascular endothelial growth factor (VEGF) trap; binds to VEGF-A, VEGF-B, and PlGF, inhibiting angiogenesis.
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once every 4 weeks (monthly). Dose adjustment is not recommended.
4 mg/kg intravenously over 1 hour every 2 weeks
None Documented
None Documented
20 days (range 11–50 days) in patients; supports every-2- or 3-week dosing. Longer half-life in bevacizumab compared to other monoclonal antibodies due to FcRn-mediated recycling.
17-18 days (terminal half-life) with clinical context supporting a dosing interval of every 2 weeks; steady-state achieved by approximately 16 weeks.
Bevacizumab (BYOOVIZ) is eliminated primarily via proteolytic catabolism, not renal or biliary excretion. No significant intact drug is excreted in urine or feces.
Primarily via the reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Renal elimination accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor